| Pascal E. Sanchez | |
|---|---|
| Photo placeholder | |
| Affiliations | University of Southern California |
| Country | USA |
| H-index | 60 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | Amyloid, Neural circuits |
Pascal E. Sanchez is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Sanchez has developed research programs that bridge basic neuroscience, translational biomarker work, and clinical interpretation. Across appointments at University of Southern California, their group has helped define how mechanistic discoveries are converted into robust disease models and clinically actionable hypotheses.
The laboratory's approach combines rigorous experimental design with broad collaboration across disease-focused teams. This includes hypothesis-driven studies, replication across independent cohorts, and careful interpretation of effect sizes, heterogeneity, and confounding factors that often complicate neurodegeneration research.
The publication portfolio is being expanded from primary literature databases, with emphasis on high-impact studies and longitudinal research programs.
Their program contributes to translational and mechanistic work in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--.
The lab emphasizes [Amyloid] to connect molecular findings with patient outcomes. The lab emphasizes Neural circuits to connect molecular findings with patient outcomes.
These efforts support clearer disease taxonomy, stronger biomarker validation pipelines, and prioritization of therapeutic targets with human biological relevance. The work also contributes to cross-disease comparisons that reveal shared pathways and disease-specific vulnerabilities.
Current priorities in Sanchez's research ecosystem include improving reproducibility across cohorts, integrating multi-omic and longitudinal clinical datasets, and clarifying which biological signals are most predictive of near-term progression and treatment response. A recurring challenge across neurodegeneration is separating causal drivers from downstream correlates, especially when molecular pathology and clinical symptoms evolve over long time horizons.
Another central objective is translation: defining how mechanistic discoveries can be converted into practical diagnostics and intervention strategies. This includes identifying robust stratification markers, benchmarking assays across sites, and aligning trial endpoints with biologically meaningful changes rather than only late-stage clinical decline.
Collaborator network pending enrichment.
[Diz-de Almeida S et al.. "Novel risk loci for COVID-19 hospitalization among admixed American populations." eLife (2024). DOI)
[de la Rosa C et al.. "In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation." Nature neuroscience (2026). DOI)
[Barahona-López C et al.. "Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map." Alzheimers Dement (2025). DOI)
[Aspra Q et al.. "Epigenome-Wide Analysis Reveals [DNA Methylation[/entities/[dna-methylation[/entities/[dna-methylation[/entities/[dna-methylation--TEMP--/entities)--FIX-- Alteration in ZFP57 and Its Target RASGFR2 in a Mexican Population Cohort with Autism." Children (Basel, Switzerland) (2022). DOI)
[Sanchez P et al.. "Causal machine learning for healthcare and precision medicine." Royal Society open science (2022). DOI)
[Fard MK et al.. "BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions." Science translational medicine (2017). DOI)
[Xia T et al.. "Adversarial counterfactual augmentation: application in Alzheimer's Disease classification." Frontiers in radiology (2022). DOI)
[Nadam J et al.. "Neuroprotective effects of erythropoietin in the rat [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- after pilocarpine-induced status epilepticus." Neurobiology of disease (2007). DOI)
[Diz-de Almeida S et al.. "Novel risk loci for COVID-19 hospitalization among admixed American populations." eLife (2024). [DOI: 10.7554/eLife.93666]https://doi.org/10.7554/eLife.93666) PubMed: 39361370
[de la Rosa C et al.. "In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation." Nature neuroscience (2026). [DOI: 10.1038/s41593-025-02151-6]https://doi.org/10.1038/s41593-025-02151-6) PubMed: 41345278
[Barahona-López C et al.. "Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map." Alzheimers Dement (2025). [DOI: 10.1002/alz.70980]https://doi.org/10.1002/alz.70980) PubMed: 41366852
[Aspra Q et al.. "Epigenome-Wide Analysis Reveals DNA Methylation Alteration in ZFP57 and Its Target RASGFR2 in a Mexican Population Cohort with Autism." Children (Basel, Switzerland) (2022). [DOI: 10.3390/children9040462]https://doi.org/10.3390/children9040462) PubMed: 35455506
[Sanchez P et al.. "Causal machine learning for healthcare and precision medicine." Royal Society open science (2022). [DOI: 10.1098/rsos.220638]https://doi.org/10.1098/rsos.220638) PubMed: 35950198
[Fard MK et al.. "BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions." Science translational medicine (2017). [DOI: 10.1126/scitranslmed.aam7816]https://doi.org/10.1126/scitranslmed.aam7816) PubMed: 29212715
[Xia T et al.. "Adversarial counterfactual augmentation: application in Alzheimer's Disease classification." Frontiers in radiology (2022). [DOI: 10.3389/fradi.2022.1039160]https://doi.org/10.3389/fradi.2022.1039160) PubMed: 37492661
[Nadam J et al.. "Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus." Neurobiology of disease (2007). [DOI: 10.1016/j.nbd.2006.10.009]https://doi.org/10.1016/j.nbd.2006.10.009) PubMed: 17166730
[Diz-de Almeida S et al.. "Novel risk loci for COVID-19 hospitalization among admixed American populations." eLife (2024). DOI)
[de la Rosa C et al.. "In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation." Nature neuroscience (2026). DOI)
[Barahona-López C et al.. "Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map." Alzheimers Dement (2025). DOI)
[Aspra Q et al.. "Epigenome-Wide Analysis Reveals DNA Methylation Alteration in ZFP57 and Its Target RASGFR2 in a Mexican Population Cohort with Autism." Children (Basel, Switzerland) (2022). DOI)
[Sanchez P et al.. "Causal machine learning for healthcare and precision medicine." Royal Society open science (2022). DOI)
[Fard MK et al.. "BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions." Science translational medicine (2017). DOI)
[Xia T et al.. "Adversarial counterfactual augmentation: application in Alzheimer's Disease classification." Frontiers in radiology (2022). DOI)
[Nadam J et al.. "Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus." Neurobiology of disease (2007). DOI)
[Diz-de Almeida S et al.. "Novel risk loci for COVID-19 hospitalization among admixed American populations." eLife (2024). [DOI: 10.7554/eLife.93666]https://doi.org/10.7554/eLife.93666) PubMed: 39361370
[de la Rosa C et al.. "In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation." Nature neuroscience (2026). [DOI: 10.1038/s41593-025-02151-6]https://doi.org/10.1038/s41593-025-02151-6) PubMed: 41345278
[Barahona-López C et al.. "Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map." Alzheimers Dement (2025). [DOI: 10.1002/alz.70980]https://doi.org/10.1002/alz.70980) PubMed: 41366852
[Aspra Q et al.. "Epigenome-Wide Analysis Reveals DNA Methylation Alteration in ZFP57 and Its Target RASGFR2 in a Mexican Population Cohort with Autism." Children (Basel, Switzerland) (2022). [DOI: 10.3390/children9040462]https://doi.org/10.3390/children9040462) PubMed: 35455506
[Sanchez P et al.. "Causal machine learning for healthcare and precision medicine." Royal Society open science (2022). [DOI: 10.1098/rsos.220638]https://doi.org/10.1098/rsos.220638) PubMed: 35950198
[Fard MK et al.. "BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions." Science translational medicine (2017). [DOI: 10.1126/scitranslmed.aam7816]https://doi.org/10.1126/scitranslmed.aam7816) PubMed: 29212715
[Xia T et al.. "Adversarial counterfactual augmentation: application in Alzheimer's Disease classification." Frontiers in radiology (2022). [DOI: 10.3389/fradi.2022.1039160]https://doi.org/10.3389/fradi.2022.1039160) PubMed: 37492661
[Nadam J et al.. "Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus." Neurobiology of disease (2007). [DOI: 10.1016/j.nbd.2006.10.009]https://doi.org/10.1016/j.nbd.2006.10.009) PubMed: 17166730
[Diz-de Almeida S et al.. "Novel risk loci for COVID-19 hospitalization among admixed American populations." eLife (2024). DOI)
[de la Rosa C et al.. "In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation." Nature neuroscience (2026). DOI)
[Barahona-López C et al.. "Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map." Alzheimers Dement (2025). DOI)
[Aspra Q et al.. "Epigenome-Wide Analysis Reveals DNA Methylation Alteration in ZFP57 and Its Target RASGFR2 in a Mexican Population Cohort with Autism." Children (Basel, Switzerland) (2022). DOI)
[Sanchez P et al.. "Causal machine learning for healthcare and precision medicine." Royal Society open science (2022). DOI)
[Fard MK et al.. "BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions." Science translational medicine (2017). DOI)
[Xia T et al.. "Adversarial counterfactual augmentation: application in Alzheimer's Disease classification." Frontiers in radiology (2022). DOI)
[Nadam J et al.. "Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus." Neurobiology of disease (2007). DOI)
[Diz-de Almeida S et al.. "Novel risk loci for COVID-19 hospitalization among admixed American populations." eLife (2024). [DOI: 10.7554/eLife.93666]https://doi.org/10.7554/eLife.93666) PubMed: 39361370
[de la Rosa C et al.. "In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation." Nature neuroscience (2026). [DOI: 10.1038/s41593-025-02151-6]https://doi.org/10.1038/s41593-025-02151-6) PubMed: 41345278
[Barahona-López C et al.. "Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map." Alzheimers Dement (2025). [DOI: 10.1002/alz.70980]https://doi.org/10.1002/alz.70980) PubMed: 41366852
[Aspra Q et al.. "Epigenome-Wide Analysis Reveals DNA Methylation Alteration in ZFP57 and Its Target RASGFR2 in a Mexican Population Cohort with Autism." Children (Basel, Switzerland) (2022). [DOI: 10.3390/children9040462]https://doi.org/10.3390/children9040462) PubMed: 35455506
[Sanchez P et al.. "Causal machine learning for healthcare and precision medicine." Royal Society open science (2022). [DOI: 10.1098/rsos.220638]https://doi.org/10.1098/rsos.220638) PubMed: 35950198
[Fard MK et al.. "BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions." Science translational medicine (2017). [DOI: 10.1126/scitranslmed.aam7816]https://doi.org/10.1126/scitranslmed.aam7816) PubMed: 29212715
[Xia T et al.. "Adversarial counterfactual augmentation: application in Alzheimer's Disease classification." Frontiers in radiology (2022). [DOI: 10.3389/fradi.2022.1039160]https://doi.org/10.3389/fradi.2022.1039160) PubMed: 37492661
[Nadam J et al.. "Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus." Neurobiology of disease (2007). [DOI: 10.1016/j.nbd.2006.10.009]https://doi.org/10.1016/j.nbd.2006.10.009) PubMed: 17166730
[Diz-de Almeida S et al.. "Novel risk loci for COVID-19 hospitalization among admixed American populations." eLife (2024). DOI)
[de la Rosa C et al.. "In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation." Nature neuroscience (2026). DOI)
[Barahona-López C et al.. "Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map." Alzheimers Dement (2025). DOI)
[Aspra Q et al.. "Epigenome-Wide Analysis Reveals DNA Methylation Alteration in ZFP57 and Its Target RASGFR2 in a Mexican Population Cohort with Autism." Children (Basel, Switzerland) (2022). DOI)
[Sanchez P et al.. "Causal machine learning for healthcare and precision medicine." Royal Society open science (2022). DOI)
[Fard MK et al.. "BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions." Science translational medicine (2017). DOI)
[Xia T et al.. "Adversarial counterfactual augmentation: application in Alzheimer's Disease classification." Frontiers in radiology (2022). DOI)
[Nadam J et al.. "Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus." Neurobiology of disease (2007). DOI)
[Diz-de Almeida S et al.. "Novel risk loci for COVID-19 hospitalization among admixed American populations." eLife (2024). [DOI: 10.7554/eLife.93666]https://doi.org/10.7554/eLife.93666) PubMed: 39361370
[de la Rosa C et al.. "In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation." Nature neuroscience (2026). [DOI: 10.1038/s41593-025-02151-6]https://doi.org/10.1038/s41593-025-02151-6) PubMed: 41345278
[Barahona-López C et al.. "Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map." Alzheimers Dement (2025). [DOI: 10.1002/alz.70980]https://doi.org/10.1002/alz.70980) PubMed: 41366852
[Aspra Q et al.. "Epigenome-Wide Analysis Reveals DNA Methylation Alteration in ZFP57 and Its Target RASGFR2 in a Mexican Population Cohort with Autism." Children (Basel, Switzerland) (2022). [DOI: 10.3390/children9040462]https://doi.org/10.3390/children9040462) PubMed: 35455506
[Sanchez P et al.. "Causal machine learning for healthcare and precision medicine." Royal Society open science (2022). [DOI: 10.1098/rsos.220638]https://doi.org/10.1098/rsos.220638) PubMed: 35950198
[Fard MK et al.. "BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions." Science translational medicine (2017). [DOI: 10.1126/scitranslmed.aam7816]https://doi.org/10.1126/scitranslmed.aam7816) PubMed: 29212715
[Xia T et al.. "Adversarial counterfactual augmentation: application in Alzheimer's Disease classification." Frontiers in radiology (2022). [DOI: 10.3389/fradi.2022.1039160]https://doi.org/10.3389/fradi.2022.1039160) PubMed: 37492661
[Nadam J et al.. "Neuroprotective effects of erythropoietin in the rat hippocampus after pilocarpine-induced status epilepticus." Neurobiology of disease (2007). [DOI: 10.1016/j.nbd.2006.10.009]https://doi.org/10.1016/j.nbd.2006.10.009) PubMed: 17166730
The study of Pascal E. Sanchez has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.